Publication in refereed journal
香港中文大学研究人员 ( 现职)
| 马碧如教授 (肿瘤学系) |
| 莫树锦教授 (肿瘤学系) |
| 陈林教授 (肿瘤学系) |
全文
| 数位物件识别号 (DOI) http://dx.doi.org/10.1007/s11912-012-0233-0 |
引用次数
Web of Sciencehttp://aims.cuhk.edu.hk/converis/portal/Publication/21WOS source URL
其它资讯
摘要The positive results of sorafenib have unveiled a new direction of research in the management of hepatocellular carcinoma (HCC). Since then intensive efforts have been focused on development of novel management strategy to further improve the outcome for patients with HCC. Emerging data have suggested that tumor progression of HCC is driven by a number of deregulated signaling pathways and/or epigenetic mechanism. Thus much effort is dedicated to identification of novel agents targeting these dysregulated pathways. Combinations of targeted therapeutics and transarterial chemoembolization (TACE), or different systemic therapeutics also hold the promise to improve treatment outcome beyond sorafenib. This review aims to summarize the current status of clinical development of treatment in HCC. Perspectives on future direction of research will also be discussed.
着者Chan SL, Mok T, Ma BBY
期刊名称CURRENT ONCOLOGY REPORTS
出版年份2012
月份6
日期1
卷号14
期次3
出版社Current Medicine Group
页次257 - 266
国际标準期刊号1523-3790
电子国际标準期刊号1534-6269
语言英式英语
关键词Biologic; Gastrointestinal cancers; Liver cancer; Review; Treatment
Web of Science 学科类别Oncology; ONCOLOGY
